Loading...
Loading...
In a report published Wednesday, Canaccord Genuity analyst John Newman assumed coverage on
NPS PharmaceuticalsNPSP with a Buy rating and $42.00 price target.
In the report, Canaccord Genuity noted, “We recommend buying NPSP on recent market weakness based on its three high-priced orphan drugs with ongoing launches and upcoming FDA approval in 2014. We expect the US Gattex and EU Restive launches to perform well in 2014 and believe Natpara revenue estimates remain low.”
NPS Pharmaceuticals closed on Tuesday at $23.38.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in